FDAsafety guidance66% confidence
Data Standards Program Strategic Plan and Board
Source: FDA
Why This Matters
Why this matters: provides agency context on safety guidance that may shape timing or evidence expectations for Glenmark; the same agency is already in play for this signal, so precedent weight is higher.
Regulatory Analysis
The Data Standards Strategy reinforces CDER’s ongoing commitment to the development, implementation, and maintenance of a comprehensive data standards program that will facilitate the efficient and effective review of regulatory submissions. This helps bring safe and effective products to market.
Supporting Context
- Therapeutic area
- Dermatology · Psoriasis
- Sub-indication
- General
Related signal: FDA Acceptance of Calcipotriene Supplement by Glenmark